<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562417</url>
  </required_header>
  <id_info>
    <org_study_id>CER 478/14</org_study_id>
    <nct_id>NCT02562417</nct_id>
  </id_info>
  <brief_title>Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex</brief_title>
  <official_title>Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sugammadex is used as a reversal drug for rocuronium- or vecuronium-induced neuromuscular
      block during general anaesthesia. IV dexamethasone is injected as a prophylactic measure
      against postoperative nausea and vomiting. Recent animal data have shown that dexamethasone
      may impair the reversal effect of sugammadex. The objective of this randomised controlled
      trial is to confirm in the clinical practice these preliminary results.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change of practice in the department
  </why_stopped>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 90% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 80% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean recovery time for T4/T1 ratio &gt; 70% after sugammadex administration</measure>
    <time_frame>surgical procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>No IV dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive an equivalent volume of normal saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 0.1 mg/kg of dexamethasone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <arm_group_label>No IV dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV dexamethasone</intervention_name>
    <arm_group_label>IV dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled to undergo microlaryngoscopy and ear-nose-throat endoscopic
             procedures

        Exclusion Criteria:

          -  contraindication to dexamethasone administration

          -  contraindication to sugammadex administration

          -  contraindication to rocuronium administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <state>VAud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>Program Director, Regional Anaesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

